Long-term use of botulinum toxin type A in children with cerebral palsy: Treatment consistency

European Journal of Paediatric Neurology

Volumn 13, Issue 5, 2009, Pages 421-429

  Molenaers, Guy ^a,b   Schörkhuber, Verena ^c   Fagard, Katrien ^c   Van Campenhout, Anja ^a,b   De Cat, Jos ^b   Pauwels, Petra ^b   Ortibus, Els ^b   De Cock, Paul ^b   Desloovere, Kaat ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UZ Pellenberg   (Belgium)

Author keywords

Botulinum toxin type A; Cerebral palsy; Long term treatment; Multi level treatment; Treatment consistency

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; BONE MALFORMATION; CEREBRAL PALSY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GAIT DISORDER; HEMIPLEGIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MUSCLE CONTRACTURE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; QUADRIPLEGIA; TREATMENT RESPONSE; WALKING DIFFICULTY;

BIOMECHANICS; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LONG-TERM CARE; LONGITUDINAL STUDIES; MALE; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; NEUROSURGICAL PROCEDURES; PARALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68449085342     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2008.07.008     Document Type: Article

References (51)

1. Koman L.A., Paterson Smith B., and Shilt J.S. Cerebral palsy. Lancet 363 (2004) 1619-1631
2. Boyd R.N., and Hays R.M. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 8 Suppl. 5 (2001) 1-20
3. Dabney K.W., Lipton G.E., and Miller F. Cerebral palsy. Pediatrics 9 (1997) 81-88
4. Berweck S., and Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Movement Disord 19 Suppl. 8 (2004) 162-167
5. Graham H.K. Botulinum toxin A in cerebral palsy: functional outcomes. J Pediatr 137 (2000) 300-303
6. Molenaers G., Desloovere K., Fabry G., and De Cock P. The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg 88 (2006) 161-170
7. Koman L.A., Mooney III J.F., Smith B., Goodman A., and Mulvaney T. Management of cerebral palsy with botulinum-a toxin: preliminary investigation. J Pediatr Orthop 13 (1993) 489-495
8. Koman L.A., Mooney III J.F., Smith B.P., Goodman A., and Mulvaney T. Management of spasticity in cerebral palsy with botulinum-a toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14 (1994) 229-303
9. Calderon-Gonzalez R., Calderon-Sepulveda R., Rincon-Reyes M., Garcia-Ramirez J., and Mino-Arango E. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 10 (1994) 284-288
10. Cosgrove A.P., Corry I.S., and Graham H.K. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36 (1994) 386-396
11. Massin M., and Allington N. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 19 (1999) 362-365
12. Koman L.A., Mooney III J.F., Smith B.P., Walker F., and Leon J.M. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 20 (2000) 108-115
13. Hesse S., Brandl-Hesse B., Seidel U., Doll B., and Gregoric M. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with botulinum toxin A. Restor Neurol Neurosci 17 (2000) 1-8
14. Boyd R.N., Pliatsios V., Starr R., Wolfe R., and Graham H.K. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 42 (2000) 32-41
15. Suputtitada A. Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A. Am J Phys Med Rehabil 79 (2000) 320-326
16. Ubhi T., Bhakta B.B., Ives H.L., Allgar V., and Roussounis S.H. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 83 (2000) 481-487
17. Slawek J., and Klimont L. Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results. Eur J Neurol 10 (2003) 313-317
18. Sarioglu B., Serdaroglu G., Tutuncuoglu S., and Ozer E.A. The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol 29 (2003) 299-301
19. El-Etribi M.A., Salem M.E., El-Shakankiry H.M., El-Kahky A.M., and El-Mahboub S.M. The effect of botulinum toxin type-A injection on spasticity, range of motion and gait patterns in children with spastic diplegic cerebral palsy: an Egyptian study. Int J Rehabil Res 27 (2004) 275-281
20. Backheit A.M., Severa S., Cosgrove A., et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43 (2001) 234-238
21. Galli M., Crivellini M., Santambrogio G.C., Fazzi E., and Motta F. Short-term effects of "botulinum toxin a" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. Funct Neurol 16 (2001) 317-323
22. Mall V., Berweck S., Kirschner J., et al. Die Therapie spastischer Bewegungsstörungen im Kindesalter mit Botulinumtoxin A. Klin Neurophys 32 (2001) 218-224
23. Papadonikolakis A.S., Vekris M.D., Korompilias A.V., et al. Botulinum A toxin for treatment of lower limb spasticity in cerebral palsy. Acta Orthop Scand 74 (2003) 749-755
24. Koman L.A., Paterson Smith B., and Balkrishnan R. Spasticity associated with cerebral palsy in children. Pediatr Drugs 5 (2003) 11-23
25. Molenaers G., Desloovere K., and De Cat J. Botulinumtoxin A bei der Behandlung der infantilen Zerebralparese. Orthopäde 33 (2004) 1119-1128
26. Greene P., Fahn S., and Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9 (1994) 213-217
27. Göschel H., Wohlfarth K., Frevert J., Dengler R., and Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol 147 (1997) 96-102
28. Jankovic J., and Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 45 (1995) 1743-1746
29. Mejia N., Vuong K.D., and Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20 (2005) 592-597
30. Koman L.A., Brashear A., Rosenfeld S., et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108 (2001) 1062-1071
31. Herrmann J., Geth K., Mall V., et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55 (2004) 732-735
32. ®) for cervical dystonia. Adv Ther 22 (2005) 49-55
33. Zuber M., Sebald M., Bathien N., de Recondo J., and Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 45 (1995) 204
34. Boyd R.N., Graham J.E.A., Nattrass G.R., and Graham H.K. Medium-term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 6 Suppl. 4 (1999) 37-45
35. Desloovere K., Molenaers G., Decat J., et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol 49 (2007) 56-61
36. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 42 (2000) 816-824
37. Molenaers G., Desloovere K., Eyssen M., De cat J., Jonkers I., and De Cock P. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 6 4 (1999) S51-S57
38. Palisano R., Rosenbaum P., Walter S., Russell D., Wood E., and Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39 (1997) 214-223
39. Hsiung G.Y.R., Das S.K., Ranawaya R., Lafontaine A.L., and Suchowersky O. Long-term efficacy of botulinum toxin a in treatment of various movement disorders over a 10-year period. Mov Disord 17 (2002) 1288-1293
40. Haussermann P., Marczoch S., Klinger C., et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19 (2004) 303-308
41. Snir M., Weinberger D., Bourla D., et al. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 136 (2003) 99-105
42. Delgado M.R. The use of botulinum toxin type A in children with cerebral palsy: a retrospective study. Eur J Neurol 6 Suppl. 4 (1999) 11-18
43. Gormley M.E., Gaebler-Spira D., and Delgado M.R. Use of botulinum toxin type a in pediatric patients with cerebral palsy: a three-center retrospective chart review. J Child Neurol 16 (2001) 113-118
44. Linder M., Schindler G., Michaelis U., et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol 8 Suppl. 5 (2001) 120-126
45. Desloovere K., Molenaers G., Jonkers I., De Cat J., De Borre L., Nijs J., et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 8 5 (2001) 75-87
46. Heinen F., Schroeders A.S., Fietzek U., and Berweck S. When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. Mov Disord 21 11 (2006) 2029-2030
47. Goldstein. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21 3 (2006) 189-192
48. Dressler D., Munchau A., Bhatia K.P., Quinn N.P., and Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?. Eur Neurol 47 (2002) 118-121
49. Metaxiotis D., Siebel A., and Doederlein L. Repeated botulinum toxin a injections in the treatment of spastic equinus foot. Clin Orthop Relat Res 394 (2002) 177-185
50. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 18 (1998) 124-131
51. Linder-Lucht M., Kirschner J., Herrmann J., et al. Why do children with cerebral palsy discontinue therapy with botulinum toxin A?. Dev Med Child Neurol 48 (2006) 319-320